Penserra Capital Management LLC Takes $67,000 Position in Insulet Corporation $PODD

Penserra Capital Management LLC acquired a new position in shares of Insulet Corporation (NASDAQ:PODD) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 216 shares of the medical instruments supplier’s stock, valued at approximately $67,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Sequoia Financial Advisors LLC grew its holdings in shares of Insulet by 2.3% during the second quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock worth $634,000 after purchasing an additional 45 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its position in Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock worth $2,222,000 after buying an additional 48 shares during the period. Mather Group LLC. boosted its position in Insulet by 4.4% during the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock worth $360,000 after buying an additional 48 shares during the period. Brooklyn Investment Group grew its holdings in Insulet by 7.0% during the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock worth $209,000 after acquiring an additional 52 shares during the last quarter. Finally, Cooper Financial Group increased its position in Insulet by 5.7% in the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock valued at $283,000 after acquiring an additional 58 shares during the period.

Wall Street Analyst Weigh In

PODD has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. Leerink Partners upped their price target on Insulet from $355.00 to $385.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Canaccord Genuity Group increased their price target on Insulet from $399.00 to $428.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Wolfe Research lifted their price objective on Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $374.10.

Insulet Stock Down 1.2%

Shares of NASDAQ:PODD opened at $332.67 on Friday. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The business’s 50-day moving average is $323.89 and its 200-day moving average is $311.52. The company has a market capitalization of $23.40 billion, a price-to-earnings ratio of 101.12, a P/E/G ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same period in the previous year, the company posted $1.08 earnings per share. The firm’s revenue for the quarter was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.39% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.